Last reviewed · How we verify
ZM-H1505R
At a glance
| Generic name | ZM-H1505R |
|---|---|
| Sponsor | Shanghai Zhimeng Biopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB (PHASE3)
- A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB (PHASE2)
- A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R (PHASE1)
- A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZM-H1505R CI brief — competitive landscape report
- ZM-H1505R updates RSS · CI watch RSS
- Shanghai Zhimeng Biopharma, Inc. portfolio CI